应用原生质体融合法选育林可霉素高产菌株

将林可霉素产生菌N65—2^#、S78—1^#的原生质体分别热灭活和紫外灭活，并将灭活原生质体用PEG融合，从中获得92-201^#融合株，其摇瓶效价分别较N65—2^#、S78—1^#提高17％、52％，且色素分泌少，传代稳定性强。     

口服或阴道用米索前列醇用于人工流产术前宫口扩张的比较

目的 :比较在人工流产术前阴道或口服用米索前列醇后宫口扩张的临床效果。方法 :将 16 1例行人工流产术的早孕妇女分成 3组。第 1组 5 3例和第 2组 5 7例于术前 1h分别经阴道用米索前列醇和口服米索前列醇各 4 0 0 μg ,第 3组为对照组5 1例 ,术前不用任何药物。结果 :第 1组和第 2组宫口扩张有效率分别是 92 % (49/ 5 3)和 89% (5 1/5 7) ,明显高于对照组 0 (0 / 5 1,P <0 .0 1) ;前 2组术中无需使用局部麻醉 (0 / 5 3和 0 / 5 7) ,而对照组则有 74 % (38/ 5 1)的病人需加用局部麻醉 (P <0 .0 1) ;前 2组术中出血量为 (7±s 4 )mL和 (7± 3)mL ,也少于对照组 (12± 4 )mL ,差异有非常显著意义 (P <0 .0 1)。阴道用米索前列醇组与口服米索前列醇组相比 ,术中扩宫口作用差异无显著意义 (P >0 .0 5 ) ,但口服用药组不良反应多于阴道用药组。结论 :阴道用米索前列醇组、口服米索前列醇组术中扩宫口作用肯定 ,出血量小、不良反应轻 ,两者疗效相似     

诱发型一氧化氮合酶在人类鼻黏膜上皮细胞中的表达

目的　探讨人类鼻黏膜上皮细胞应答炎性刺激因子白细胞介素 1 β(interleukin 1 β ,IL 1 β)和肿瘤坏死因子 (tumornecrosisfactor α ,TNF α) ,合成诱发型一氧化氮合酶 (induciblenitricoxidesynthase ,iNOS)的能力及其机制 ,以及类固醇药物对上皮细胞的影响。方法　将人类鼻黏膜上皮细胞(包括鼻息肉上皮细胞 ,下鼻甲上皮细胞 )进行无血清原代细胞培养 ,分别加入各种不同浓度的炎性刺激因子 (IL 1 β和TNF α)以及地塞米松 ,采用原位杂交的方法检测不同条件下iNOSmRNA的水平。结果　①不论用IL 1 β或是TNF α刺激 ,iNOSmRNA水平均随浓度的增加 ,时间的延长而增加 ,尤以鼻息肉上皮细胞明显。但当浓度到一定水平后 ,iNOSmRNA水平不再继续升高 ;②用IL 1 β +TNF α共同刺激 ,iNOSmRNA水平要高于单纯用其中的一种 (P <0 .0 1 ) ,同样鼻息肉上皮细胞iNOSmRNA水平要高于下鼻甲上皮细胞 ;③加入地塞米松后 ,被炎性因子诱发的iNOSmRNA升高的水平下降。当地塞米松浓度为 4 0ng/ml以上时 ,iNOSmRNA水平不再继续下降。 结论　①IL 1 β和TNF α上调人类鼻黏膜上皮细胞合成的iNOSmRNA水平 ,鼻息肉上皮细胞更为活跃。它的机制可能是通过核因子 κB途径 ;②地塞米松降低这种上调作用 ,它的机制可能是通过阻断核     

母儿血型不合IgG抗体效价≥1：512是否提示胎儿病情严重

目的：探讨母儿血型不合IgG抗体效价≥1：512是否提示胎儿病情严重。方法：对6例血清IgG抗A（B）抗体效价≥1：512的母儿血型不合孕妇，进行羊膜腔穿刺抽样羊水作胆红素、IgG抗体效价和胎儿血型物质测定，抽取其新生儿脐血作胎儿血型、胆红素检测及Coombs试验。结果：孕妇血清IgG抗体效价与新生儿溶血病的严重程度并不密切相关。结论：不能单纯以孕妇血清抗体效价的高低作为判断胎儿溶血的唯一依据。     

Wolfram syndrome: phenotype and novel mutation in two Taiwanese siblings.

Wolfram syndrome (WS) is a rare autosomal recessive neurodegenerative disorder. The responsible gene, WFS1, was identified in 1998 and over 66 mutations have been reported since then. We report 2 siblings in a Taiwanese family with WS. They had similar clinical courses, including successive development of diabetes mellitus, optic atrophy, diabetes insipidus, hearing impairment, and urological complications from age 5 to 15 years. Rapid progression of systemic and neurological symptoms was noted in the elder brother. Mutation analysis of the 2 probands revealed compound heterozygotes of 1 novel and 1 previously reported mutation. Their parents and an asymptomatic sibling were carriers of 1 mutation.     

Proton magnetic resonance spectroscopy improves outcome prediction in perinatal CNS insults.

OBJECTIVE: Prediction of neurologic outcome is difficult in neonates with acute nervous system injury. Previous studies using proton magnetic resonance spectroscopy ((1)H-MRS) have been used to predict short-term neurologic outcome in neonates with a variety of neurologic insults. We were interested in determining the effectiveness of combining clinical evaluation and spectroscopy obtained at the time of injury in predicting neurologic outcome at 24 months. STUDY DESIGN: We studied 33 neonates with acute central nervous system injury, 5.8+/-3.7 days of injury, owing to hypoxic-ischemic encephalopathy. Neonates were assessed using clinical variables (initial arterial pH, initial blood glucose, Sarnat score, electroencephalography) and spectroscopy (NAA/Cho, NAA/Cre, Cho/Cre, and lactate). Neonates were divided into two outcome groups: good/moderate and poor. Differences between the groups were assessed using chi(2) and t-test analyses. We analyzed the best predictors of outcome using discriminant analysis and calculated sensitivity, specificity, positive, and negative predictive values for each variable independently and in combination. RESULTS: There were significant differences between the good/moderate and poor outcome for the Sarnat score, EEG, lactate, and NAA/Cho. Spectroscopy combined with clinical variables improved sensitivity, but not specificity for predicting outcome. The presence of lactate had the best individual predictive value. Combination of the clinical with the MRS variables had the highest predictive value. CONCLUSION: Proton magnetic resonance spectroscopy done early after injury improves the ability to predict neurologic outcome at 24 months of age.     

Population-based case-control study of CYP11A gene polymorphism and breast cancer risk.

The CYP11A gene encodes the cholesterol side-chain cleavage enzyme (P450scc) that catalyzes the first and rate-limiting step for the biosynthesis of sex hormones. A pentanucleotide repeat [(TAAAA)n] polymorphism in the 5' of the CYP11A gene has been reported to be related to the risk of polycystic ovary syndrome, an inherited endocrine disorder characterized by hyperandrogenemia. We investigated the association of this polymorphism with breast cancer risk in a population-based case-control study conducted among Chinese women in Shanghai. Genotype assays were completed for 1015 incident breast cancer cases and 1082 community controls. Three common alleles with 4, 6, or 8 TAAAA repeats were identified in the study population. The frequency of the 8 repeat allele was more common in cases (12.6%) than controls (8.5%) (odds ratio = 1.6, 95% confidence interval = 1.3-1.9; P < 0.0001). Compared to subjects who did not carry this allele, adjusted odds ratios were 1.5 (95% confidence interval = 1.2-1.9) and 2.9 (1.3-6.7) (P for trend, <0.001), respectively, for those who carried one and two copies of this allele. This positive association was observed in both pre- and postmenopausal women and all strata defined by major breast cancer risk factors, including years of menstruation, body mass index, and waist-to-hip ratio. The results from this study indicate that the TAAAA repeat polymorphism near the promoter region of the CYP11A gene may be an important susceptibility factor for breast cancer risk.